NASDAQ:ZURA Zura Bio (ZURA) Stock Price, News & Analysis → The CHIPS Act Motherlode (From True Market Insiders) (Ad) Free ZURA Stock Alerts $6.05 +0.05 (+0.83%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$5.83▼$6.3550-Day Range$2.05▼$6.0552-Week Range$2.00▼$13.00Volume439,335 shsAverage Volume265,546 shsMarket Capitalization$260.69 millionP/E RatioN/ADividend YieldN/APrice Target$18.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Zura Bio alerts: Email Address Zura Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside211.3% Upside$18.83 Price TargetShort InterestHealthy3.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$534,998 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.51) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector265th out of 921 stocksBiological Products, Except Diagnostic Industry30th out of 148 stocks 3.6 Analyst's Opinion Consensus RatingZura Bio has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZura Bio has only been the subject of 2 research reports in the past 90 days.Read more about Zura Bio's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.07% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zura Bio has recently decreased by 6.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldZura Bio does not currently pay a dividend.Dividend GrowthZura Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZURA. Previous Next 3.1 News and Social Media Coverage News SentimentZura Bio has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.Search Interest12 people have searched for ZURA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows9 people have added Zura Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zura Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $534,998.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.80% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zura Bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Zura Bio are expected to decrease in the coming year, from ($0.51) to ($0.74) per share.Price to Book Value per Share RatioZura Bio has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zura Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Zura Bio Stock (NASDAQ:ZURA)Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.Read More ZURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZURA Stock News HeadlinesApril 25, 2024 | insidertrades.comKiran Nistala Buys 3,195 Shares of Zura Bio Limited (NASDAQ:ZURA) StockMay 12, 2024 | americanbankingnews.comZura Bio (NASDAQ:ZURA) PT Raised to $21.00May 10, 2024 | finance.yahoo.comZura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 9, 2024 | investorplace.comZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024May 9, 2024 | finance.yahoo.comZura Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 4, 2024 | msn.comPiper Sandler Initiates Coverage of Zura Bio (ZURA) with Overweight RecommendationMay 3, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Zura Bio (ZURA)May 1, 2024 | finance.yahoo.comZura Bio Limited (ZURA)April 28, 2024 | 247wallst.comThese Biotechs and IPOs Inspire Big Insider BuyingApril 26, 2024 | investing.comZura Bio executive acquires $24,999 in company sharesApril 26, 2024 | investing.comZura Bio EVP Kiran Nistala buys $10,000 in company sharesApril 25, 2024 | finance.yahoo.comDirector Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)April 20, 2024 | msn.comZura Bio stock jumps on plans to raise $112.5M in private financingApril 18, 2024 | markets.businessinsider.comZura Bio Announces Private Placement Of $112 MLn Of Class A Shares; Stock UpApril 18, 2024 | marketwatch.comZura Bio Shares Rise 16% After Private Placement Valued at $112.5MApril 18, 2024 | finance.yahoo.comZura Bio Announces Oversubscribed $112.5 Million Private PlacementApril 8, 2024 | businesswire.comZura Bio Announces Robert Lisicki as CEO and DirectorApril 3, 2024 | benzinga.comZura Bio Stock (NASDAQ:ZURA), Analyst Ratings, Price Targets, PredictionsApril 2, 2024 | finance.yahoo.comInsider Buyers At Zura Bio Recover Some Losses, But Still Down US$165kMarch 31, 2024 | finance.yahoo.comZura Bio Ltd (ZURA) Reports Full Year 2023 Financial Results Amidst Leadership TransitionMarch 28, 2024 | businesswire.comZura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive OfficerMarch 4, 2024 | businesswire.comZura Bio Announces Participation at March ConferencesFebruary 14, 2024 | finance.yahoo.comWe're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn RateFebruary 3, 2024 | msn.comZura Bio Issues Regulation FD Disclosure StatementFebruary 2, 2024 | finance.yahoo.comZura Bio Announces Participation at February Investor ConferencesSee More Headlines Receive ZURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today5/19/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ZURA CUSIPN/A CIK1855644 WebN/A Phone858-247-0520FaxN/AEmployees14Year FoundedN/APrice Target and Rating Average Stock Price Target$18.83 High Stock Price Target$26.00 Low Stock Price Target$10.00 Potential Upside/Downside+211.3%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-64.56% Return on Assets-50.33% Debt Debt-to-Equity RatioN/A Current Ratio6.17 Quick Ratio4.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book4.17Miscellaneous Outstanding Shares43,090,000Free Float36,285,000Market Cap$260.69 million OptionableNot Optionable Beta0.15 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David BradyHead of Business DevelopmentDr. Someit Sidhu M.D. (Age 34)Founder, CEO & Director Mr. Robert Lisicki (Age 56)President & COO Mr. Verender S. Badial (Age 52)Chief Financial Officer Dr. Gary Whale Ph.D. (Age 50)Chief Technology Officer Dr. Michael D. Howell Ph.D. (Age 46)Chief Scientific Officer & Head of Translational Science Ms. Kimberly Ann Davis (Age 56)Chief Legal Officer & Secretary Ms. Theresa Lowry (Age 50)Chief Human Resources Officer Dr. Kiran Nistala MBBS (Age 51)Ph.D., Chief Medical Officer & Head of Development More ExecutivesKey CompetitorsCompass TherapeuticsNASDAQ:CMPXAcumen PharmaceuticalsNASDAQ:ABOSAgenusNASDAQ:AGENInnate PharmaNASDAQ:IPHAOptheaNASDAQ:OPTView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCBought 450,009 shares on 5/15/2024Ownership: 1.044%Amit MunshiBought 159,744 shares on 4/22/2024Total: $499,998.72 ($3.13/share)Michael HowellBought 7,987 shares on 4/22/2024Total: $24,999.31 ($3.13/share)Kiran NistalaBought 3,195 shares on 4/22/2024Total: $10,000.35 ($3.13/share)Amit MunshiBought 117,647 shares on 6/5/2023Total: $499,999.75 ($4.25/share)View All Insider TransactionsView All Institutional Transactions ZURA Stock Analysis - Frequently Asked Questions Should I buy or sell Zura Bio stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zura Bio in the last twelve months. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZURA shares. View ZURA analyst ratings or view top-rated stocks. What is Zura Bio's stock price target for 2024? 6 equities research analysts have issued 12 month price targets for Zura Bio's shares. Their ZURA share price targets range from $10.00 to $26.00. On average, they predict the company's share price to reach $18.83 in the next year. This suggests a possible upside of 211.3% from the stock's current price. View analysts price targets for ZURA or view top-rated stocks among Wall Street analysts. How have ZURA shares performed in 2024? Zura Bio's stock was trading at $4.67 at the start of the year. Since then, ZURA shares have increased by 29.6% and is now trading at $6.05. View the best growth stocks for 2024 here. When is Zura Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ZURA earnings forecast. How were Zura Bio's earnings last quarter? Zura Bio Limited (NASDAQ:ZURA) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.07. Who are Zura Bio's major shareholders? Zura Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Affinity Asset Advisors LLC (1.04%). Insiders that own company stock include Amit Munshi, Kiran Nistala and Michael Howell. View institutional ownership trends. How do I buy shares of Zura Bio? Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ZURA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.